Table 2 Comparison of baseline characteristics among survivors and nonsurvivors

 Age, months

72

60 (36, 96)

60 (30, 98)

36 (31, 105)

0.60

 Boys, n (%)

72

45 (62.5)

41 (68.3)

4 (33.3)

0.04

 PRISM III

72

8 (5, 12)

8 (5, 11)

12 (8.7, 17.5)

0.005

 Duration of illness, days

72

7 (5, 10)

7 (5, 9.5)

9 (5, 12)

0.38

 Ferritin, μg/L

62

668 (420, 2714)

666 (382, 2653)

1806 (443, 4727)

0.53

  Normal (< 500), n (%)

17 (27.4)

15 (28.8)

2 (20)

0.42

  Mild (> 500–2000), n (%)

26 (41.9)

23 (44.2)

3 (30)

  Moderate (> 2000–10,000), n (%)

13 (21)

10 (19.2)

3 (30)

  Severe (> 10,000), n (%)

6 (9.7)

4 (7.8)

2 (20)

 Hemoglobin, g/dl

72

8.7 (7.4, 10.2)

8.6 (7.5, 10.5)

8.1 (6.8, 10.1)

0.48

 Total leukocyte count cells/mm³

72

14,000 (9820, 18,000)

14,090 (10,200, 17,500)

12465 (7020, 21,080)

0.39

 Platelet count cells/mm³

72

18,000 (44,000, 80,000)

19,000 (48,000, 80,000)

31000 (11,500, 100,000)

0.39

 Albumin, g/dl

58

2.2 (2.1, 2.6)

2.3 (2.1, 2.6)

2.1 (1.9, 2.2)

0.05

 Severe hypoalbuminemia (< 2.5 g/dl), n (%)

58

39 (54.2)

30 (50)

9 (75)

0.14

 Lactate, mmol/L

72

1.6 (1.1, 2.6)

1.6 (1, 1.8)

3.0 (1.85, 9.8)

0.04

 Hematological dysfunction, n (%)

72

68 (94.4)

56 (93.3)

12 (100)

0.60

 Respiratory failure, n (%)

72

40 (55.5)

28 (46.6)

12 (100)

0.001

  ARDS, n (%)

72

23 (31.9)

13 (21.7)

10 (83.3)

< 0.0001

  Mechanical ventilation, n (%)

72

34 (47.2)

22 (36.7)

12 (100)

0.0001

 Shock, n (%)

72

20 (28.2)

12 (20.3)

8 (66.7)

0.003

  VIS on day 1

72

0 (0, 10)

0 (0,0)

10 (0,30)

0.0001

 AKI, n (%)

72

15 (20.8)

10 (16.7)

5 (41.7)

0.02

  RRT, n (%)

72

5 (6.9)

2 (3.3)

3 (25)

0.03

 CNS dysfunction, n (%)

72

10 (13.9)

6 (10)

4 (33.3)

0.05

 Coagulopathy (INR > 1.5), n (%)

56

12 (21.4)

10 (21.3)

2 (22.2)

1.0

 PELOD-2 score

  Day 1

72

3 (2, 7)

2 (2, 5)

7 (7, 9)

< 0.0001

  Day 2

67

2 (1, 5)

2 (1, 5)

6 (4, 7)

0.001

  Day 3

64

2 (1, 5)

2 (1, 4)

4 (1, 6)

0.32